A Wisconsin Republican congressman on the Rural Domestic Energy Council remains hopeful for progress in nationwide E15 fuel negotiations. Rep. Derrick Van Orden says the talks are delicate but believes a deal can be reached despite previous industry disruptions.
Wisconsin Representative Derrick Van Orden, who sits on the Rural Domestic Energy Council, says he remains hopeful about reaching an agreement on E15 fuel despite ongoing complications in the negotiations.
The Third District Republican told Brownfield that while the nationwide E15 discussions are extremely delicate, he maintains optimism that negotiators will reach a successful agreement.
Van Orden explained that many believed the E15 matters had been settled previously, but complications arose when an industry representative disrupted the process. “I’m not going to say who, but somebody threw a, from industry, not […]” he said, declining to provide specific details about the disruption.
The congressman’s comments highlight the ongoing challenges in finalizing E15 fuel policy at the national level, as stakeholders continue working toward a resolution.
The Muslim holy month of Ramadan began Wednesday in Gaza as Palestinians gathered to pray in the debris of destroyed mosques and temporary shelters. Many worshippers mourned the loss of their sacred spaces while attempting to observe the religious period amid widespread destruction.
Verisk, a New Jersey-based insurance data analytics company, reported fourth-quarter earnings that surpassed Wall Street predictions, driving shares up nearly 10% in pre-market trading. The strong performance came despite challenges from reduced weather activity and a smaller federal contract.
Insulet Corporation surpassed Wall Street projections for the fourth quarter, driven by increased sales of its tubeless insulin delivery devices. The company reported a 31% revenue jump and announced plans for significant stock buybacks in 2026.
Charles River Laboratories announced Wednesday it expects 2026 profits to exceed Wall Street predictions, citing recovering demand from biotechnology companies for drug research services. The Massachusetts-based contract research firm reported fourth-quarter earnings that beat analyst expectations despite some revenue challenges.